<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293383</url>
  </required_header>
  <id_info>
    <org_study_id>MCB 0902</org_study_id>
    <nct_id>NCT01293383</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects. A Single Centre, Prospective, Randomised, Double-blinded, Vehicle-controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to to investigate the safety of LEO 90105 compared with its
      vehicle after multiple administration (twice daily, 5 days) in healthy Japanese male
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin irritation</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LEO 90105</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90105</intervention_name>
    <description>Ointment</description>
    <arm_group_label>LEO 90105</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male subjects

          -  Aged 20 to 40 years inclusive

          -  Subjects without signs of skin irritation (erythema, dryness, roughness or scaling) on
             the test site

          -  Subjects willing to follow the study procedures and complete the study

          -  Subjects having understood and signed a written informed consent

          -  Subjects without abnormal in physiological test and clinical test in screening, and
             also judged as possible to participant the study by investigators

        Exclusion Criteria:

          -  Subjects with Body mass Index (BMI ) (body weight(kg)/height (m)²) outside the range
             18-25 kg/m2(18≤BMI&lt;25)

          -  Subjects with history of alcohol, chemical or drug abuse

          -  Subjects with history of allergic reaction to any content of the study medication

          -  Subjects with systemic or cutaneous disease that could in any way confound
             interpretation of the study results (e.g. atopic dermatitis, eczema, psoriasis)

          -  Subjects with known sensitivity to any component of any of the formulations being
             tested

          -  Subjects with known hepatic, renal or cardiac disorders

          -  Subjects using systemic, locally injected or inhaled corticosteroids within 4 weeks of
             study start (Day 1)

          -  Subjects using systemic vitamin D analogues,vitamin D or calcium supplements within 4
             weeks of study start (Day 1)

          -  Subjects using any drug (systemic or topical) within 2 weeks of study start (Day 1)

          -  Subjects using non-marketed/other investigational products one month prior to or 5
             half lives (for those the half life is longer than one month) and during the trial is
             not permitted

          -  Subjects with any abnormality found at medical interview before administration of the
             test drug, which will affect the clinical study as judged by the investigator

          -  Subjects with history of or active photo-induced or photo-aggravated disease (abnormal
             response to the sun light)

          -  Subjects with exposure to excessive or chronic ultraviolet (UV) radiation i.e.,
             sunbathing, tanning salon use, phototherapy) within four weeks prior to study start
             (Day 1) or planned during the study period

          -  Subjects with scars, moles, sunburn, or other blemishes in the test area which would
             interfere with grading

          -  Subjects whose partner wishes to become pregnant but is unwilling to use birth control
             during the study

          -  Subjects with any condition which, in the opinion of the investigator, would place the
             subject at an unacceptable risk if he participated in the study

          -  Subjects with any disease which are contradictions for treatment of the investigation
             products or for which treatment with the investigation products needs to be carefully
             considered (Subjects with any of the following conditions present on the area(s) to be
             treated with study medication: viral (e.g., herpes or varicella) lesions of the skin,
             fungal or bacterial skin infections, parasitic infections, skin manifestations in
             relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae
             atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers or wounds)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masanari Shiramoto, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hakata Clinic LTA Clinical Pharmacology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hakata Clinic LTA Clinical Pharmacology Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

